The new coronavirus is known to affect humans in a number of different ways, some of which have a serious infection and others do not. Recent research suggests that the amount of cholesterol a person carries may be a key factor in the severity of COVID-19 infection.
“We found that the S1 subunit of SARS-2-S binds to cholesterol, and possibly to HDL components, to boost virus intake in vitro.
“Our findings reveal that B type 1 acts as a host factor that promotes SARS-CoV-2 entry and may help explain viral tropism, identify a possible molecular link between COVID-19 and lipoprotein metabolism, and highlight B type 1 as a potential therapeutic goal. SARS-CoV-2 infection.
“Type 1 B is a cell-surface HDL receptor that mediates the selective uptake of cholesterol esters and other lipid components of receptor-bound HDL particles.”
The study concluded that the SARS-CoV-2 S protein binds to cholesterol, and HDL enhances the entry of SARS-CoV-2 through the SARS-2-S1 protein.
The researchers then found that blocking type 1 B and neutralizing it inhibited the infection.
They say targeting a type B receptor could be a potential pathway for future treatment.
The researchers wrote about this discovery and said: “The results of our study show that SR-B1 facilitates the binding, entry and infection of SARS-CoV-2.
“Thus, type 1 B could be a therapeutic target for limiting SARS-CoV-2 infection.”
In another study published in the US National Institutes of Health, a class 1 type 1 human waste receptor was investigated as a new receptor for the hepatitis C virus.
The study noted: “The low-density lipoprotein (LDL) receptor has been shown to mediate the internalization of HCV by binding to virus-associated LDL particles, a phenomenon common to many viruses that, like HCV, belong to the Flaviviridae family.
“We have identified the receptor responsible for the binding of E2 to human liver cells as a receptor for the human class B type I scavenger (SR-BI).
“The E2-SR-BI interaction is very selective because neither the mouse-SR-BI nor the closely related receptor for the removal of human CD36 has been able to bind E2.”
The study further indicated the potential power of type 1 B in reducing the risk of coronavirus binding to cholesterol and thereby reducing the severity of infection.